How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 140-146

  Havrilesky, Laura J ^a,b   Chino, Junzo P ^a   Myers, Evan R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

Cost effectiveness; Endometrial cancer; Lymph node dissection; Value of information

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE OUTCOME; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER REGISTRY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; ENDOMETRIUM CANCER; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT;

EID: 84885304374     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.025     Document Type: Article

References (21)

1. Cragun J, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. A retrospective analysis of selective lymphadenectomy in apparent early stage endometrial cancer. J Clin Oncol 2005;23(16): 3668-75.
2. Chan JK, Kapp DS, Cheung MK, Osann K, Shin JY, Cohn D, et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 2007;97(5): 605-11.
3. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin III F, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56(1): 29-33.
4. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373(9658):125-36 [Epub 2008/12/17].
5. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100(23): 1707-16 [Epub 2008/11/27].
6. CreasmanWT, Mutch DE, Herzog TJ. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid?Gynecol Oncol 2010;116(3):293-4 [Epub 2009/11/10].
7. Naumann RW. The role of lymphadenectomy in endometrial cancer: was the ASTEC trial doomed by design and are we destined to repeat that mistake? Gynecol Oncol 2012;126(1):5-11 [Epub 2012/05/05].
8. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006;24(11):1055-68 [Epub 2006/10/28].
9. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006 [x, 237 p. p.].
10. Wong WB, Ramsey SD, Barlow WE, Garrison Jr LP, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials 2012;33(6):1117-23 [Epub 2012/09/18].
11. Chino JP, Jones E, Berchuck A, Secord AA, Havrilesky LJ. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys 2012;82(5):1872-9 [Epub 2011/06/07].
12. Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Kulasingam S. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2008;26(25):4144-50 [Epub 2008/09/02].
13. Jewell EL, Kulasingam S, Myers ER, Alvarez Secord A, Havrilesky LJ. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. Gynecol Oncol 2007;107(3):532-40 [Epub 2007/09/29].
14. Havrilesky LJ, Garfield CF, Barnett JC, Cohn DE. Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. Gynecol Oncol 2012;125(3):631-4 [Epub 2012/03/27].
15. Stout NL, Pfalzer LA, Springer B, Levy E, McGarvey CL, Danoff JV, et al. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther 2012;92(1):152-63 [Epub 2011/09/17].
16. Jewell EL, Smrtka M, Broadwater G, Valea F, Davis DM, Nolte KC, et al. Preference-based utility scores for adverse events associated with the treatment of gynecologic cancers. Int J Gynecol Cancer 2013;23(6):1158-66, http:// dx.doi.org/10.1097/IGC.0b013e318299e2a6.
17. Hoomans T, Fenwick EA, Palmer S, Claxton K. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value Health 2009;12(2):315-24 [Epub 2008/07/29].
18. Schmidt C. Researchers consider value-of-information theory for selecting trials. J Natl Cancer Inst 2010;102(3):144-6 [Epub 2010/01/29].
19. Hoomans T, Fenwick EA, Palmer S, Claxton K. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value Health 2008;12(2):315-24 [Epub 2008/07/29].
20. Siegel R, NaishadhamD, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1): 10-29 [Epub 2012/01/13].
21. Hassan C, Hunink MG, Laghi A, Pickhardt PJ, Zullo A, Kim DH, et al. Valueof- information analysis to guide future research in colorectal cancer screening. Radiology 2009;253(3):745-52 [Epub 2009/10/01].